Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Olaparib plus bevacizumab bij ovariumcarcinoom: definitieve OS-resultaten van PAOLA-1
aug 2023 | Gynaecologische oncologie